Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
114.64
+2.10 (1.87%)
Jun 18, 2025, 4:00 PM - Market closed
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $144.71, which forecasts a 26.23% increase in the stock price over the next year. The lowest target is $135 and the highest is $160.
Price Target: $144.71 (+26.23%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 9, 2025.
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $142 → $145 | Buy | Maintains | $142 → $145 | +26.48% | May 9, 2025 |
| Stifel | Stifel | Strong Buy Initiates $143 | Strong Buy | Initiates | $143 | +24.74% | Apr 10, 2025 |
| Benchmark | Benchmark | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +17.76% | Dec 23, 2024 |
| Barclays | Barclays | Buy Maintains $150 → $160 | Buy | Maintains | $150 → $160 | +39.57% | Dec 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $141 → $143 | Buy | Maintains | $141 → $143 | +24.74% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
197.90M
from 167.13M
Increased by 18.41%
Revenue Next Year
235.24M
from 197.90M
Increased by 18.87%
EPS This Year
6.23
from -0.22
EPS Next Year
6.70
from 6.23
Increased by 7.51%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 209.8M | 255.3M | 321.2M | ||
| Avg | 197.9M | 235.2M | 276.5M | ||
| Low | 181.4M | 208.8M | 240.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.5% | 29.0% | 36.5% | ||
| Avg | 18.4% | 18.9% | 17.5% | ||
| Low | 8.6% | 5.5% | 2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.53 | 7.74 | 9.09 | ||
| Avg | 6.23 | 6.70 | 8.21 | ||
| Low | 5.88 | 4.38 | 7.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 24.2% | 35.8% | ||
| Avg | - | 7.5% | 22.6% | ||
| Low | - | -29.7% | 12.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.